# Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors

> **NCT04450901** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Y Biologics Inc.** · enrollment: 90 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** YBL-006
- **DRUG:** YBL-006
- **DRUG:** YBL-006
- **DRUG:** YBL-006
- **DRUG:** YBL-006
- **DRUG:** YBL-006
- **DRUG:** YBL-006
- **DRUG:** YBL-006

## Key facts

- **NCT ID:** NCT04450901
- **Lead sponsor:** Y Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-01
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2022-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04450901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04450901, "Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04450901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*